No interaction studies have been performed. Co-treatment with CYP3A inhibitors, including cobicistat-containing products, should be expected to increase the risk of systemic side effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side effects, in which case patients should be monitored for systemic corticosteroid side effects.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
